RecallRadar

FDA Drug recall D-0533-2018

Vardenafil HCl USP (trihydrate) for prescription compounding, packaged in a) 5g (NDC 58597-8575-2)

On 2018-02-28 the FDA classified a Class II recall of Vardenafil HCl USP (trihydrate) for prescription compounding, packaged in a) 5g (NDC 58597-8575-2) by American Pharmaceutical Ingredients, citing CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0533-2018
ClassificationClass II
Statusterminated
Initiated2018-02-09
Published2018-02-28
Last updated2026-09-13 11:52 UTC
CompanyAmerican Pharmaceutical Ingredients
DistributionUS

Product

Vardenafil HCl USP (trihydrate) for prescription compounding, packaged in a) 5g (NDC 58597-8575-2); b) 100g (NDC 58597-8575-6);c) 500g (NDC 58597-8575-7); d) 1000g (NDC 58597-8575-8), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327

Reason

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Identifiers

code_infoLot #: a) 070717-2, Exp. 05/31/2020; b) 070717-1, Exp. 05/31/2020; c) 070717-1, Exp. 05/31/2020; d) 070717-1, Exp. 05/31/2020.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0533-2018%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.